Exercise of Options

RNS Number : 3579L

Evgen Pharma PLC

11 January 2016

 

For immediate release

11 January 2016

Evgen Pharma plc

("Evgen" or the "Company")

Exercise of Options

The Company announces that it has received a notice to exercise options over 272,000 ordinary shares in Evgen.  Such options were issued to the executor of the late Dr Barry Furr OBE , a scientific consultant to the Company between 2011 and 2014 and a former Chief Scientist of AstraZeneca.  The options were granted under the 2011 Share Option Plan and have an exercise price of 5 pence per share.  Accordingly, the Company has issued 272,000 new Ordinary Shares of 0.25 pence each ("New Ordinary Shares").  The New Ordinary Shares rank pari passu with the Company's existing issued Ordinary Shares.  Application has been made to admit the New Ordinary Shares to trading on AIM and dealings in these shares are expected to commence at 8:00am on 14 January 2016.  On admission, the Company will have 73,142,862 shares in issue.

Total voting rights

There are no shares held in treasury, therefore following the admission of the New Ordinary Shares the total number of voting rights in the Company will be 73,142,862. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest under the Disclosure and Transparency Rules.

Enquiries:

Evgen Pharma plc                                            Dr Stephen Franklin, CEO www.evgen.com	[phone]
Buchanan                                            Mark Court, Sophie Cowles, Stephanie Watson	[phone]
Northland Capital Partners Limited Matthew Johnson, Gerry Beaney, Margarita Mitropoulou (Corporate Finance) John Howes (Corporate Broking)	[phone]

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke.  It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer.  The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.  Evgen Pharma commenced operations in January 2008 and is based in Liverpool, UK, at the Liverpool Science Park.  For further information please visit www.evgen.com

 

END

 

 

MSCQVLFBQFFEBBF